Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950901 | 0.79 | SLC2A1 (0.37) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL15581401 | 0.75 | HTR1A (0.50) | — | |
| SCHEMBL5002428 | 0.74 | MEN1 (0.34) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL19955073 | 0.73 | PLA2G1B (0.33) | — | |
| SCHEMBL24299500 | 0.72 | SLC2A1 (0.33) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL1705440 | 0.71 | — | — | |
| SCHEMBL12788325 | 0.70 | HTR1A (0.56) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL950518 | 0.70 | SLC2A1 (0.32) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL3823316 | 0.70 | SLC2A1 (0.32) | CHRM2CHRM4CHRM1CHRM3SLC2A1 | |
| SCHEMBL22282172 | 0.69 | SIGMAR1 (0.34) | CHRM2CHRM4CHRM1CHRM3SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2018-04-05 | — | — | US | disclosed |
| US-9914755-B2 | Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized | ALLERGAN, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914755-B2 | Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized | ALLERGAN, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | ALLERGAN, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | ALLERGAN, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160200767-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9266927-B2 | Cyclosporin A analogs | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266927-B2 | Cyclosporin A analogs | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | TSLP, CHP1, PPP3R1 | CHRM2 3885/4885CHRM4 3983/4885CHRM1 4407/4885 |
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | CHRM2 3266/4885CHRM4 2692/4885CHRM1 3441/4885 |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | CHP1, UACA, CRYAB | CHRM2 1761/4885CHRM4 1501/4885CHRM1 2073/4885 |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | CHRM2 3903/4885CHRM4 3644/4885CHRM1 4247/4885 |
| US-20160200767-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | CHRM2 3266/4885CHRM4 2692/4885CHRM1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.